Down syndrome and Alzheimer's disease: Common pathways, common goals
Document Type
Article
Abstract
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments.
Publication Date
6-1-2015
Publication Title
Alzheimer's and Dementia
ISSN
15525260
E-ISSN
15525279
Volume
11
Issue
6
First Page
700
Last Page
709
PubMed ID
25510383
Digital Object Identifier (DOI)
10.1016/j.jalz.2014.10.007
Recommended Citation
Hartley, Dean; Blumenthal, Thomas; Carrillo, Maria; DiPaolo, Gilbert; Esralew, Lucille; Gardiner, Katheleen; Granholm, Ann Charlotte; Iqbal, Khalid; Krams, Michael; Lemere, Cynthia; Lott, Ira; Mobley, William; Ness, Seth; Nixon, Ralph; Potter, Huntington; Reeves, Roger; Sabbagh, Marwan; Silverman, Wayne; Tycko, Benjamin; Whitten, Michelle; and Wisniewski, Thomas, "Down syndrome and Alzheimer's disease: Common pathways, common goals" (2015). Neurology. 852.
https://scholar.barrowneuro.org/neurology/852